INTRODUCTION: Up to 50% of diabetic patients with neuropathy suffer from chronic pain, namely painful diabetic neuropathy (PDN), an unmet medical need with significant impact on quality of life. Gabapentin is widely used for PDN, albeit with frequent dose-limiting effects. Trazodone, an antidepressant with multi-modal action, has shown promising results when given at low doses as an add-on to gabapentin. Upon previous clinical trials and experimental evidence, a fixed-dose combination (FDC) of both compounds, at low doses, was developed for neuropathic pain. METHODS: This was a phase II, randomized, double-blind, placebo and reference controlled, dose-finding, multicenter, international, prospective study. Male and female diabetic patients aged 18-75 years and affected by PDN were eligible for enrolment. Patients were randomized (1:1:1:1:2 ratio) to trazodone and gabapentin (Trazo/Gaba) 2.5/25 mg t.i.d. for 8 weeks, Trazo/Gaba 5/50 mg t.i.d. for 8 weeks, Trazo/Gaba 10/100 mg t.i.d. for 8 weeks, gabapentin (Gaba), or placebo (PLB). The aim of the study was to collect preliminary information on the effect of the 3 different FDCs of Trazo/Gaba on pain intensity based on the 11-point numeric rating score (NRS) after 8 weeks of treatment. The secondary objectives were the evaluation of the percentage of responders, neuropathic pain symptoms, anxiety, sleep, quality of life, safety, and tolerability. The primary efficacy endpoint was evaluated with last observation carried out forward (LOCF), using an analysis of covariance (ANCOVA), including treatment and centers as factors and baseline as covariate and applying linear contrast test, excluding the active treatment. Only if the linear contrast test was significant (p < 0.05), the step-down Dunnett test would be used to determine the minimum effective dose significantly different from PLB. If linearity was not verified, an adjusted ANCOVA model and comparisons with Dunnett test were performed. Before the application of the ANCOVA model, the non-significance of interaction treatment per baseline was verified. RESULTS: A total of 240 patients were included in the modified intention-to-treat (m-ITT) population: 39 in Trazo/Gaba 2.5/25 mg, 38 in Trazo/Gaba 5/50 mg, 37 in Trazo/Gaba 10/100 mg, 83 in PLB, and 43 in Gaba. After 8 weeks of treatment, changes of the average daily pain score based on the 11-point NRS from baseline were - 2.52 ± 2.31 in Trazo/Gaba 2.5/25 mg group, - 2.24 ± 1.96 in Trazo/Gaba 5/50 mg group, - 2.46 ± 2.12 in Trazo/Gaba 10/100 mg group, - 1.92 ± 2.21 in Gaba group, and - 2.02 ± 1.95 in the PLB group. The linear contrast test did not result in significant differences (p > 0.05) among treatment groups. Consequently, the minimum effective dose against PLB was not determined. The multiple comparison with Dunnett adjustment did not show any statistically significant differences vs. PLB after 8 weeks of treatment: Trazo/Gaba 2.5/25 mg (95% confidence interval (CI) - 1.2739, 0.2026; p = 0.1539); Trazo/Gaba 5/50 mg (95% CI - 0.9401, 0.5390; p = 0.5931); Trazo/Gaba 10/100 mg (95% CI - 1.0342, 0.4582; p = 0.4471). However, patients receiving the lowest dose of Trazo/Gaba 2.5/25 mg showed a statistically significant difference to PLB after 6 weeks of treatment (95% CI - 1.6648, - 0.2126; p = 0.0116). Positive results were also found for responder patients, other items related to the pain, anxiety, depression, sleep, and quality of life, consistently in favor to the lowest Trazo/Gaba FDC. Two serious adverse events (SAEs) occurred but were judged unrelated to the study treatment. Treatment-emergent adverse events (TEAEs) were mainly mild-to-moderate in intensity and involved primarily nervous system, gastrointestinal disorders, and investigations. CONCLUSIONS: The primary end point of the study was the change from baseline of the average daily pain score based on the 11-point NRS after 8 weeks of treatment. While the primary endpoint was not reached, patients treated with Trazo/Gaba 2.5/25 mg t.i.d. showed statistically significant improvement of pain and other scores after 6 weeks and reported consistent better results in comparison to PLB on primary and secondary endpoints for the overall study duration. According to these results, the lowest dose of Trazo/Gaba FDC may be the best candidate for further clinical development to confirm the potential benefits of the FDC drug for this condition. CLINICAL TRIAL REGISTRATION: NCT03749642.

Angelini Pharma S p A Rome Italy

Departement d'Endocrinologie Centre de Recherche Clinique G H M les Portes du Sud Venissieux France

Department of Diabetes Endocrinology and Metabolism George Eliot Hospital NHS Trust Nuneaton UK

Department of Neurology Regional Hospital Pardubice Pardubice Czech Republic

Diabetes Research Unit Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK

Neurosanatio s r o Litomyšl Czech Republic

NZOZ Neuromed M i M Nastaj Sp P Lublin Poland

Silmedic Sp z o o Katowice Poland

Warwick Medical School University of Warwick Coventry UK

See more in PubMed

Smith BH, Hébert HL, Veluchamy A. Neuropathic pain in the community: prevalence, impact, and risk factors. Pain. 2020;161(Suppl 1):S127–S137. doi: 10.1097/j.pain.0000000000001824. PubMed DOI

Blyth FM. Global burden of neuropathic pain. Pain. 2018;159(3):614–617. doi: 10.1097/j.pain.0000000000001127. PubMed DOI

van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654–662. doi: 10.1016/j.pain.2013.11.013. PubMed DOI

Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi: 10.1016/S1474-4422(14)70251-0. PubMed DOI PMC

Tesfaye S, Brill S, Eerdekens M, Labrador MM, Petersen G, de Rooij Peek A, Reta A, Ryan D, Schaper N, Tölle T, Truini A, Ziegler D. Diagnosis, management and impact of painful diabetic peripheral neuropathy: a patient survey in four European countries. J Diabetes Complications. 2023;37(4):108417. doi: 10.1016/j.jdiacomp.2023.108417. PubMed DOI

Shillo P, Sloan G, Greig M, Hunt L, Selvarajah D, Elliott J, Gandhi R, Wilkinson ID, Tesfaye S. Painful and painless diabetic neuropathies: what is the difference? Curr Diab Rep. 2019;19(6):32. doi: 10.1007/s11892-019-1150-5. PubMed DOI PMC

Selvarajah D, Sloan G, Teh K, Wilkinson ID, Heiberg-Gibbons F, Awadh M, Kelsall A, Grieg M, Pallai S, Tesfaye S. Structural brain alterations in key somatosensory and nociceptive regions in diabetic peripheral neuropathy. Diabetes Care. 2023;46(4):777–785. doi: 10.2337/dc22-1123. PubMed DOI

Khurana RC. Treatment of painful diabetic neuropathy with trazodone. JAMA. 1983;250(11):1392. doi: 10.1001/jama.1983.03340110016015. PubMed DOI

Wilson RC. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. J Am Podiatr Med Assoc. 1999;89(9):468–471. doi: 10.7547/87507315-89-9-468. PubMed DOI

Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, Moore RA. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD0007938. doi: 10.1002/14651858.CD007938.pub4. PubMed DOI PMC

Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14(10):536–546. doi: 10.1017/s1092852900024020. PubMed DOI

Lipone P, Ehler E, Nastaj M, Palka-Kisielowska I, Cruccu G, Truini A, Di Loreto G, Del Vecchio A, Pochiero I, Comandini A, Calisti F, Cattaneo A. Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study. CNS Drugs. 2020;34(11):1177–1189. doi: 10.1007/s40263-020-00760-2. PubMed DOI PMC

Olivero G, Grilli M, Vergassola M, Bonfiglio T, Padolecchia C, Garrone B, Di Giorgio FP, Tongiani S, Usai C, Marchi M, Pittaluga A. 5-HT2A-mGlu2/3 receptor complex in rat spinal cord glutamatergic nerve endings: a 5-HT2A to mGlu2/3 signalling to amplify presynaptic mechanism of auto-control of glutamate exocytosis. Neuropharmacology. 2018;1(133):429–439. doi: 10.1016/j.neuropharm.2018.02.030. PubMed DOI

Cisani F, Roggeri A, Olivero G, Garrone B, Tongiani S, Di Giorgio FP, Pittaluga A. Acute low dose of trazodone recovers glutamate release efficiency and mGlu2/3 autoreceptor impairments in the spinal cord of rats suffering from chronic sciatic ligation. Front Pharmacol. 2020;17(11):1108. doi: 10.3389/fphar.2020.01108. PubMed DOI PMC

Quintero JE, Dooley DJ, Pomerleau F, Huettl P, Gerhardt GA. Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ α2δ-1 subunit. J Pharmacol Exp Ther. 2011;338(1):240–245. doi: 10.1124/jpet.110.178384. PubMed DOI PMC

Garrone B, di Matteo A, Amato A, Pistillo L, Durando L, Milanese C, Di Giorgio FP, Tongiani S. Synergistic interaction between trazodone and gabapentin in rodent models of neuropathic pain. PLoS ONE. 2021;16(1):e0244649. doi: 10.1371/journal.pone.0244649. PubMed DOI PMC

Ruggieri A, Picollo R, Del Vecchio A, Calisti F, Dragone P, Comandini A, Rosignoli MT, Cattaneo A, Donath F, Wedemeyer RS, Todorova-Sanjari M, Warnke A, Blume HH. Investigations on dose proportionality and drug–drug interaction for a fixed-dose combination of trazodone and gabapentin. Int J Clin Pharmacol Ther. 2021;59(1):71–86. doi: 10.5414/CP203845. PubMed DOI

Koltzenburg M, McMahon S, Tracey I, Turk DC, editors. Wall and Melzack’s textbook of pain. 6. London: Saunders, imprint of Elsevier Ltd.; 2013.

Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manag. 2005;29(4):401–410. doi: 10.1016/j.jpainsymman.2004.06.018. PubMed DOI

Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, Boureau F. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108(3):248–257. doi: 10.1016/j.pain.2003.12.024. PubMed DOI

Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. San Antonio: Psychological Corporation; 1996.

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x. PubMed DOI

Morin CM. Insomnia: psychological assessment and management. New York: Guilford Press; 1993.

Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307. doi: 10.1016/S1389-9457(00)00065-4. PubMed DOI

Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–1727. doi: 10.1007/s11136-012-0322-4. PubMed DOI PMC

Guy W. ECDEU assessment manual for psychopharmacology. Rockville: National Institute of Mental Health, Psychopharmacology Research Branch; 1976. revised, pp. 217–22, 313–31, 534–7.

Mallinckrodt CH, Tamura RN, Tanaka Y. Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. J Psychiatr Res. 2011;45(9):1202–1207. doi: 10.1016/j.jpsychires.2011.03.001. PubMed DOI

Neuropathic pain—pharmacological management. NICE clinical guideline 173. https://www.nice.org.uk/guidance/cg173/evidence/full-guideline-pdf-4840898221.

Guettler N, Rajappan K, Nicol E. The impact of age on long QT syndrome. Aging (Albany NY). 2019;11(24):11795–11796. doi: 10.18632/aging.102623. PubMed DOI PMC

Oggianu L, Garrone B, Fiorentini F, Del Bene F, Rosignoli MT, Di Giorgio FP, Kaminski RM. PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: translational PK-PD modeling from nonclinical to clinical development. Clin Transl Sci. 2023;16(4):606–617. doi: 10.1111/cts.13472. PubMed DOI PMC

Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice ASC, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157(8):1599–1606. doi: 10.1097/j.pain.0000000000000492. PubMed DOI PMC

Boussageon R, Howick J, Baron R, Naudet F, Falissard B, Harika-Germaneau G, Wassouf I, Gueyffier F, Jaafari N, Blanchard C. How do they add up? The interaction between the placebo and treatment effect: a systematic review. Br J Clin Pharmacol. 2022;88(8):3638–3656. doi: 10.1111/bcp.15345. PubMed DOI PMC

Finnerup NB, Haroutounian S, Baron R, Dworkin RH, Gilron I, Haanpaa M, Jensen TS, Kamerman PR, McNicol E, Moore A, Raja SN, Andersen NT, Sena ES, Smith BH, Rice ASC, Attal N. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy. Pain. 2018;159(11):2339–2346. doi: 10.1097/j.pain.0000000000001340. PubMed DOI PMC

Marchettini P, Wilhelm S, Petto H, Tesfaye S, Tölle T, Bouhassira D, Freynhagen R, Cruccu G, Lledó A, Choy E, Kosek E, Micó JA, Späth M, Skljarevski V, Lenox-Smith A, Perrot S. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy? Eur J Pain. 2016;20(3):472–482. doi: 10.1002/ejp.763. PubMed DOI

See more in PubMed

ClinicalTrials.gov
NCT03749642